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Redyeastrice(RYR)ismadebyfermentingtheyeastMonascuspurpureusoverrice.Itisasourceofnatural
red food colorants, a food garnish and a traditional medication. Results of the current study demonstrated
that polar fractions of the RYR preparations contained herbal-drug interaction activity, which if left
unremoved, enhanced P-glycoprotein activity and inhibited the major drug metabolizing cytochromes
P450, i,e, CYP 1A2, 2C9 and 3A4. The data from Caco-2 cell absorption and animal model studies further
demonstrated that the pharmacokinetic modulation effect by RYR preparations containing the polar
fractions (‘‘untreated’’ preparation) was greater than that from RYR preparations with the polar fractions
removed (‘‘treated’’ preparation). The data indicates a potential for herb-drug interactions to be present in
RYRcommonlysoldasnutritionalsupplementswhenthepolarfractionsarenotremovedandthisshouldbe
taken into consideration when RYR is consumed with medications, including verapamil.
R
edyeastrice(RYR)isatraditionalfoodspiceconsumedthroughoutAsia.Alsoknownas‘‘redkoji’’,itsfood
and medicinal values date back to more than a thousand years, with the first recorded use being in
800A.D
1,2. RYR is derived from rice that has been allowed to ferment with the mold Monascus purpureus
(M.purpureus).RYRcontainsstarch,sugar,sterols,isoflavones,pigments,fattyacidsandyeastpolyketides
3,4.The
classes of polyketides structures that arise from the fermentation process are called monacolins, and the major
monacolin found in RYR is monacolin K, which is identical in structure to lovastatin. Other polyketides in RYR
are structural analogs of monacolin K
5.
Lovastatin is a reversible competitive inhibitor of 3-hydroxy-3-methyl-glutary CoA (HMG CoA) reductase,
which is the key enzyme that controls cholesterol biosynthesis. It has been used as a cholesterol lowering drug
6,7.
20–40 mg lovastatin significantly reduced levels of cholesterol and low density lipoprotein (LDL)
8. In clinical
studies of hypercholesterolemic patients, individuals receiving a dose of 2,400 mg/day of RYR had 18% decrease
intotalcholesterol,23%decreaseinLDLcholesteroland15%decreaseintriglycerolconcentrations
3.Inthesame
clinicalstudy,adailydoseof2,400 mgofRYRpowdercontainingabout5 mgofmonacolinKreducedcholesterol
levelsinhypercholesterolemicsubjectstoadegreeequivalenttowhatistypicallyobservedwiththeuseat20 mgof
lovastatin.
Whilst the non-polar fraction of RYR has been studied extensively
9, there has been no studies to-date which
investigates the pharmacokinetic activity of the polar fraction of RYR extract. In this study, we have used in vitro
P-glycoprotein (P-gp) activity assay, P450 CYP inhibition assay and Caco-2 cell absorption study and in vivo
(animal study) systems to compare the pharmacokinetic activities of extracts from raw RYR (untreated prepara-
tion) and the extract of RYR after removal of the polar fraction by soaking RYR in water overnight (treated
preparation).
Results
HPLC analysis. The chemical profiles of ‘‘untreated’’ and ‘‘treated’’ RYR were revealed by HPLC analysis. 5 mlo f
‘‘untreated’’and‘‘treated’’RYRextractsat50 mg/mlwereinjectedandanalyzedbyHPLCsystem(Figure1).The
area under the curves was measured by the software, Class-VP (Shimadzu). In untreated and treated RYR ex-
tracts, the distribution of peak area at retention time between 20–40 min, were 95.6% and 98.2% respectively
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RYRextractsareorganicinnatureandtheseorganicfractionsprofile
remains with water extraction. Table 1 also revealed that the polar
fractions (retention time between 0–20 min) were 60% removed by
water extraction in treated RYR samples. In addition, washed
fractions of the ‘‘treated RYR’’ extract was found to contain mona-
scumic acid and citrinin (a nephotoxin)
10 along with many other
unknown compounds when analyzed with LCMS-IT-TOF. The
monascumic acid was determined from one of the fractionated
washed fraction which showed HRMS [M1H]
1 5 216.1241 (calcd
for C10H17NO4 1 H, 216.1236) and characteristic MS fragments
which are correspond to losses of water molecule ([M-18]
1) fol-
lowed by the elimination of COOH group ([M1H245]
1)
11. Mean-
while the citrinin was determined by referring to retention time and
mass of pure citrinin purchased from Fluka.
P-gp activity assay. The influence of ‘‘untreated’’ and ‘‘treated’’ RYR
extract on P-gp activity which is the key enzyme to determine
bioavailability of drug administrated was investigated by in-vitro
P-gp activity assay. In this experiment, verapamil (P-gp subtract,
as positive control) and ‘‘treated’’ or ‘‘untreated’’ RYR extract were
incubated independently with the P-gp membrane. It was observed to
have a significant change in luminescence compared to the Na3VO4
(P-gp inhibitor) treated samples. However, the ‘‘untreated’’ RYR
extract showed more than 2-fold in enhancement in P-gp ATPase
activity when compared with the ‘‘treated’’ RYR extract.
CYP activity assay. The inhibition effect of ‘‘untreated’’ and
‘‘treated’’ RYR extract was determined by in-vitro CYP activity
assay. The luminescence signals observed in the CYP1A2, CYP2C9
and CYP3A4 activity assays are directly proportional to the enzyme
activity. The net signals from untreated (added with 1x PBS)
CYP1A2, CYP2C9 and CYP3A4 reactions represent total CYP
activity (without any inhibition). 100 mg/ml of naringenin (NG, a
CYP inhibitor) was added as negative control in the experiments.
Our results suggests that the ‘‘untreated’’ RYR extracts exhibited
stronger inhibition on CYP1A2 (about 2- fold), CYP2C9 (about 4-
fold) and CYP3A4 (about 2- fold) than the ‘‘treated’’ RYR extract at
same concentration of RYR extracts (Figure 3).
Caco-2 cell absorption assay. In vitro study using monolayers of
Caco-2 cells was conducted to evaluate the changes in intestinal
permeability of the drug tested (verapamil) with addition of ‘‘un-
treated’’ and ‘‘treated’’ RYR extracts. In the Caco-2 absorption
study, the concentrations of the samples taken from the basolateral
and apical compartments were calculated using a calibration curve
(data not shown) which was constructed by measuring the peak area
obtained from injections of verapamil standards (250 mg/ml, 125
mg/ml, 30 mg/ml, 15 mg/ml, 7.5 mg/ml and 3 mg/ml). The linear
equation for regression analysis from this calibration curve was found
to be y 5 27043x - 11153 (r
2 5 0.98). The intestinal absorption
permeability co-efficienct (Peff (A–B)) of the control was 5.99 6
0.41310
26 and that of the treated and untreated RYR extract were
7.85 6 0.83310
26 and 17.0 6 0.43310
26 respectively (Figure 4).
Animal study. The pharmacokinetic effect of ‘‘untreated’’ and
‘‘treated’’ RYR extract on co-administration of drug (verapamil)
was investigated using an animal model. In the this study, the
concentrations of verapamil present in the blood samples collected
at different time points in the animal absorption study were
Figure 1 | HPLCprofiles of ‘‘untreated’’ and ‘‘treated’’ RYR extracts weremeasured at wavelength of243nm, sampleconcentration both at 50 mg/ml.
Table 1 | Distribution (%) of area under the curve at different range
of retention times. Total peak area was the sum of all peaks area
from 0 to 40 min. The peaks area within particular retention time
(0–10 min, 10–20 min, 20–30 min and 30–40 min) were added
up and expressed in percentage over total peaks area. Retention
time 0 to 20 minutes and 20 to 40 minutes were classified as polar
fractions and organic fractions respectively
Retention time (min)
Distribution of peak (%)
Treated RYR Untreated RYR
Polar Fractions 0–10 0.8 1.2
10–20 1 3.2
Organic Fractions 20–30 33 31
30–40 65.2 64.6
www.nature.com/scientificreports
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2 5
0.998]). In this study, the rats were pre-treated with saline (control
group) and either ‘‘treated’’ or ‘‘untreated’’ RYR extract followed
with oral administration of verapamil at 10 mg/kg. After 30
minutes, the absorption of verapamil in the group that received
‘‘untreated’’ RYR was about 1.6-fold higher than the control group
and the group that received’’ treated’’ RYR (Figure 5).
Discussion
Foods, beverages and herbs are commonly consumed together with
medicinal drugs. The chemicals from food and herbs may interact
withmedicinaldrugs(e.g.grapefruitjuicehasbeenreportedtointer-
fere with the uptake of drugs
12) resulting in either the reduction or
increase of their bioavailability, which is an important pharmacoki-
netic parameter, and thus affecting treatment efficacy or tiggering
toxicity. The seriousness of food-drug interactions is dependent on
the therapeutic index of each drug. With modern drugs generally
havinglowertherapeuticindices,thereisagreaterpossibilityoftoxic
effects and changed treatment efficacy
13. P-gp is an ATP-dependent
efflux pump with broad substrate specificity. The bioavailability of a
drug is determined by its absorption, distribution, metabolism and
excretion. These processes are mainly mediated by nuclear receptor-
mediateddetoxificationsysteminvolvingavarietyofCYPs,conjuga-
tion enzymes and drug transporters (P-gp)
14–16. Among these, the
cytochrome CYP3A4 and P-gp are most important
17,18. CYP3A4
accounts for about 60% of the breakdown of clinically used drugs
19.
P-gp transports many drugs from the intestine into the bloodstream
and has been postulated to evolve as a defense mechanism against
harmful substances, such as drugs and xenobiotics. Therefore, com-
pounds that interact and inhibit the activity of P-gp and/or CYPs
may change the bioavailability of drugs. For instance, naringenin (a
CYP inhibitor) could enhance the bioavailability of verapamil in
rabbits
20, while verapamil (P-gp substrate) could enhance bioavail-
ability of ivermectin in rats
21.
Recently, RYR has been developed as a dietary supplement to
lower blood lipids, including cholesterol and triglycerides. In addi-
tion to rice starch, protein, isoflavones, fiber, sterols, and fatty acids,
RYR contains numerous biologically active constituents, including
monacolinK,whichhastheabilitytoreducebloodcholesterollevels.
Since isoflavones and sterols
22,23 found in some herbs were reported
to show inhibitory effect on P-gp, the question arose whether iso-
flavones,sterolsandothercompoundspresentinRYRcausedsimilar
effect. In orderto showthat the herb-drug interactions of RYR could
be reduced by specific treatment of the raw material, we compared
the pharmacokinetic activities of ‘‘treated’’ and ‘‘untreated’’ RYR by
in vitro assay (P-gp, CYPs and Caco-2 cell assay) and in vivo assay
(animal study).
Figure 1 suggested that the organic fractions (of retention time
20 to 40 minute), containing monacolin K and its analogs, of
‘‘untreated’’ and ‘‘treated’’ RYR were very similar. Therefore, the
blood cholesterol lowering effect (contributed by monacolin K and
its analogs) of ‘‘treated’’ RYR should be similar to the ‘‘untreated’’
RYR. The major difference in the chemical profile was in the polar
fractions (ofretention time0 to20minute)of‘‘treated’’ RYRextract,
which had smaller peak areas than ‘‘untreated’’ RYR extract
(Table 1). In conclusion, the polar compounds of RYR were effec-
tively removed by water extraction. Nevertheless, the organic profile
in the RYR remains unchanged by the extraction.
The effects of ‘‘treated’’ and ‘‘untreated’’ RYR extracts on P-gp
activity were studied. The P-gp assay kit (Promega), provided the
necessary reagents for performing luminescent P-gp ATPase assays.
P-gp,alsoknownasMDR1andABCB1,isa170 kDaintegralplasma
membrane protein that functions as an ATP-dependent drug efflux
pump and plays an important role in multi-drug resistance and
certain adverse drug-drug interactions
24. Compounds that are sub-
strates for transport by P-gp typically stimulate its ATPase activity.
P-gpdependentdecreasesinluminescencereflectATPconsumption
by P-gp; thus the greater the decrease in signal, the higher the P-gp
activity. The difference in luminescence signal between Na3VO4-
treated samples and untreated samples (control) represented the
basal P-gp ATPase activity, while the difference in luminescence
signal between Na3VO4-treated samples and sample with the test
compound (i.e. ‘‘treated’’ or ‘‘untreated’’ RYR extract) represented
P-gp ATPase activity in the presence of the test compound. In
Figure 2, the ‘‘untreated’’ RYR extract showed more than 2-fold
decrease in P-gp ATPase activity as compared to the ‘‘treated’’
RYR extract. This suggested that compounds which interacted with
P-gp ATPase in ‘‘untreated’’ RYR extract have been removed in the
‘‘treated’’ RYR samples and that these compounds activated P-gp.
In addition to P-gp, to determine whether the ‘‘treated’’ and
‘‘untreated’’ RYR extracts had effects on the cytochrome P450
(CYP) system, these were tested using the CYP1A2, CYP2C9 and
CYP3A4 activity assays. These assay systems included membrane
preparations containing a recombinant human CYP1A2, CYP2C9
orCYP3A4enzyme,aluminogenicsubstratespecifictotheCYP1A2,
CYP2C9 or CYP3A4 enzyme, an NADPH Regeneration System and
Luciferin Detection Reagent. In this assay, the modulation of CYP
activity by a test compound was determined by comparing the
changes from the average net signal of ‘‘untreated’’ CYP1A2,
CYP2C9 and CYP3A4 reactions with the changes observed due to
‘‘treated’’ or ‘‘untreated’’ RYR extracts. The level of luminescence
measured from the control or the test compound was directly pro-
portionaltothe CYPenzyme activity. Ourresults revealedthat addi-
tion of ‘‘untreated’’ RYR extract showed stronger inhibition of
CYP1A2,CYP2C9andCYP3A4activitywhencomparedtotheaddi-
tion of ‘‘treated’’ RYR extract (Figure 2). Since CYP1A2, CYP2C9
and CYP3A4 are known to represent over 70% of the human liver’s
ability to detoxify drugs, their inhibition by ‘‘untreated’’ RYR has
implication on the safety and efficacy of the drug when consumed
withRYR.Furthermore,thedataalsoindicatedthepresenceofasyet
uncharacterized compound(s) in the polar fraction of RYR which
inhibited the three CYPs. Since the P-gp enhancing activity of RYR
also occurred in the polar fraction of RYR, it is unclear whether the
same unknown compounds are responsible for the effects on P-gp
and CYP or that these effects are due to different herb-drug inter-
acting compounds.
To further study the pharmacokinetic effect of ‘‘treated’’ and
‘‘untreated’’ RYR extract with other drugs, a Caco-2 drug absorption
studywasperformed.InvitrostudywithCaco-2cellmonolayers(i.e.
a human colon carcinoma cell line) is a valuable tool for predicting
human in vitro intestinal permeability. Caco-2 cells express a wide
range of transporter proteins on their cell membranes similar to
those of intestinal endothelium cells
25. Thus, this cell line is ideal
intestinal absorption simulations and studies. In the experiments,
50 ml of 1xPBS (control) or ‘‘treated’’ and ‘‘untreated’’ RYR extracts
(sample concentration was 0.5 mg/ml) were added into the apical
compartment of the tissue culture plates with verapamil at 100 mg/
ml. Our data revealed that the addition of ‘‘untreated’’ RYR extract
resulted in a 2-fold increase in the net absorption of verapamil (P-gp
substrate)whencomparedwiththeadditionof‘‘treated’’RYRextract
in the Caco-2 study. Verapamil was chosen for the study on herbl-
drug interaction of RYR water soluble extract in the Caco-2 absorp-
tionstudybecauseverapamilisnotonlyawell-knownP-gpsubstrate
but also a P-gp inhibitor
26. The absorption rate of the verapamil is
determined by the P-gp activity. Therefore, the increase in absorp-
tion of verapamil by the addition of ‘‘treated’’ RYR extract revealed
the potential P-gp inhibitory effect of RYR water soluble polar
extract.
TodeterminewhethertheeffectsobservedwithCaco-2cellswhen
adding ‘‘treated’’ or ‘‘untreated’’ RYR extracts to verapamil absorp-
tion were similarly observed in an intact animal model system, the
pharmacokinetic effects of co-administration of ‘‘untreated’’ and
www.nature.com/scientificreports
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absorption study using the rat model system. The animals were pre-
treatedwith either saline(control group) or ‘‘treated’’ or ‘‘untreated’’
RYR extract. Blood samples were collected from the jugular vein of
the animal. Our data showed that at 30 minutes post-administration
of verapamil, the absorption of verapamil in the group that received
‘‘untreated’’ RYR was significantly higher (about 2-fold) than that of
the control group and the group that received ‘‘treated’’ RYR. In
other words, co-administration of ‘‘untreated’’ RYR extract with
verapamil caused over-dosage of verapamil. This finding implied
that compared to ‘‘treated’’ RYR extract, ‘‘untreated’’ RYR extract
affected the pharmacokinetics of verapamil in rats with respect to
potential herb-drug interaction by inhibiting both P-gp and CYPs.
The results of this study provide the first evidence of the differ-
ences in pharmacokinetic effects of ‘‘treated’’ and ‘‘untreated’’ RYR
extracts and suggest that the co-administration of ‘‘untreated’’ RYR
withotherCYP/P-gpsubstratedrugs(verapamilasanexample)may
result in changes in the pharmacokinetic profile (since the untreated
RYR extract could enhance drug bioavailability).
ThisstudyimpliesthatcurrentuseofRYRasadietarysupplement
when taken together with drugs/medications can potentially cause
undesirable herb-drug interactions. We have shown that CYP3A4,
which accounts for 60% of the breakdown of clinically used drugs,
wassignificantlyinhibited by‘‘untreated’’RYRextract.Wehavealso
shown that P-gp activity was significantly inhibited by addition of
‘‘untreated’’ RYR extract (Figure 2 and Figure 3C). The study also
points to the need for dietary supplement and Traditional Chinese
Medicine (TCM) manufactures to develop better and safer RYR
products for consumers by removing the polar fraction. In addition,
the study also provided evidence of potential endogenous drug
absorption modulators in M. purpureus which could explain why
only about 5 mg of monacolin K (equivalent in chemical structure
to lovastatin) in 2,400 mg of RYR powder can reduce cholesterol
levels in hypercholesterolemic patients to a similar degree as 20 mg
of lovastatin. Further studies are in progress to identify and charac-
terize these endogenous drug absorption modulator(s) in RYR.
Methods
Preparation of RYR samples. Raw Red Yeast Rice (i.e. ‘‘untreated’’ RYR) was
purchased from local supplier. The ‘‘treated’’ RYR was prepared by soaking 100 g of
RYR overnight in 500 ml of distilled water at room temperature (25uC). After
centrifugation at 4,000 rpm for 30 minutes, the supernatant was discarded and the
RYR residue was collected and dried at 60uC for 24 hour (i.e. ‘‘treated’’ RYR). The
‘‘untreated’’ and ‘‘treated’’ RYR were subsequently soaked in 50% (v/v) ethanol
overnight. The ethanol extracts were then collected and dried using a Speedvac
concentrator.Theextractsof‘‘untreated’’and‘‘treated’’RYRwereanalyzedbyHPLC,
LC-MS/MS, biochemical assays, and used in Caco-2 cell absorption study as well as
rat pharmacokinetic studies.
Chemicalsandreagents.Verapamilhydrochlorideandlovastatinwaspurchasedfrom
Aldrich-Sigma (USA). Methanol and acetonitrile were obtained from Fisher Scientific
(USA). All other reagents were standard laboratory reagents of analytical grade.
Figure 2 | The influences of ‘‘untreated’’ and ‘‘treated’’ RYR extract on
P-gp activity, final concentration of samples was 1.25 mg/ml. Data are
expressed asmean 6SD(n53).*P,0.05and**P,0.01vsthe untreated
group (UT) control value.
Figure 3 | The study of effects of ‘‘untreated’’ and ‘‘treated’’ RYR
extract on (A) CYP1A2, (B) CYP2C9 and (C) CYP3A4 activity, final
concentration of samples was 1.25 mg/ml. Data are expressed as mean
6 SD (n 5 3). *P,0.05 and **P,0.01 vs the untreated group (UT)
control value.
www.nature.com/scientificreports
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chemical profile and verapamil concentrationin the cell absorption assay and animal
experiment includes the following: LC-10AT liquid chromatograph, DGU-14A/
DGU-12Adegasser,SCL-10Asystemcontroller,SIL-10ADautoinjector,SPD-M10A
diode array detector and CTO-10A column oven. For chemical profiling, a PFP
HPLC column (15034.60 mm i.d., 3 mm particle size, Phenomenex Inc., Torrance,
CA)wasusedintheHPLCanalysis.Theflowratewassetat0.7 ml/minwithamobile
phase of 0.1% formic acid and 3% acetonitrile in distilled water. A gradient elution
was set from 3-100% of acetonitrile at 40uC for 40 mins. The detector was set at
243 nm with an injection volume of 10 ml. For cell absorption assay and animal
experiment,anOryxMonolithicC18HPLCcolumn(10033.0 mmi.d.,3mmparticle
size, Phenomenex Inc., Torrance, CA) was used in the HPLC analysis. The flow rate
wassetat0.7 ml/minwithamobilephaseof0.1%formicacidand30%acetonitrilein
distilledwater.Anisocraticelutionwassetat30%ofacetonitrileat40uC.Thedetector
was set at 318 nm with an injection volume of 10 ml.
LC-MS/MS analysis. TheLC-MS-IT-TOF system wasused to identify compounds in
the polar extract. LC-MS analysis was performed using the Shimadzu Prominence
Series LC coupled to the LCMS-IT-TOF. Prominence Series components included
two LC-20AD pumps, DGU-20A3degasser, CBM-20A system controller, SIL-20AC
auto injector and SPD-M20A PDA detector, CTO-20AC column oven, LCMS-IT-
TOF MS detector and LCMS solution ver 3.50 SP2 software. The column used was a
Shimadzu Shimpack VP-ODS packed with 4.6 mm particles (25032.0 mm i.d). The
flowratewassetat0.2 ml/minwithamobilephaseof0.1%formicacidinacetonitrile
and distilled water. A gradient elution was set 0 min 3% acetonitrile, 40 min 90%
acetonitrile,58 min95%acetonitrile,63 min3%acetonitrileandstoptime70 min.A
5 mL injection volume was used. The LCMS-IT-TOF was operated under the
following conditions: ESI in positive mode; drying gas: 1.5 L/min; CDL temperature:
200uC;interfacetemperature:250uC;MS
1scanrange:100–900 m/z,MS
2scanrange:
101 – 800 m/z.
P-Glycoprotein (P-gp) substrate assay. Pgp-Glo
TM Assay System (Promega, USA)
was used to analyze the effects of ‘‘treated’’ and ‘‘untreated’’ RYR extract on P-gp
activity.PreparationsofP-gpreactionmixturesandATPdetectionreagentweredone
in accordance with the manufacturer’s instructions with modifications as follows:
20 mlof RYR water soluble extract was prepared in different concentrations (1.25, 2.5
and 5 mg/ml); Verapamil (positive control as P-gp substrate, 0.5 mM) and Na3VO4
(P-gp inhibitor, 0.25 mM) were added into a white opaque 96-well plate (with clear
flat bottom, Costar Inc., NY). P-gp was then added into the wells containing the test
compounds and incubated at 37uC for 5 min. The reactions were initiated by the
addition of MgATP solution and left to incubate at 37uC for 40 min. Then reactions
werestoppedandluminescence wasinitiatedbyaddingATPDetectionReagenttoall
wells. The luminescences in all samples were measured by an Infinite F200 plate
reader (Tecan, Austria).
Cytochrome(CYP)1A2,2C9and3A4P450activityassay.CYP1A2A,CYP2C9and
CYP3A4 activity assay (CYP1A2, CYP2C9 and CYP3A4 P450-Glo
TM, Promega)
employs luminogenic P450 probe substrates that are derivatives of beetle luciferin, a
substratefortheluciferaseenzymewithmodification.Inbrief,theCYP1A2,CYP2C9
andCYP3A4membranesweretreatedwith12.5mlofluciferin-freewater(ascontrol),
100 mg/ml of naringenin (CYP inhibitor, as negative control) or the RYR water-
soluble extract at different concentrations (1.25 mg/ml, 2.5 mg/ml and 5 mg/ml,
drug treated) in a white opaque 96-well plate (Costar, USA). The plate was pre-
incubated at37uCfor10 minfollowedbyaddition ofNADPHRegeneration solution
to start the reaction. The mixture was further incubated at 37uC for 20 min before
detection of luminescence by addition of ATP Detection Reagent to all wells to stop
reaction. The NADPH Regeneration solution and ATP Detection Reagent were
prepared in accordance with the manufacturer’s instructions. The luminescences in
all samples were measured by an Infinite F200 plate reader (Tecan).
Cell culture. Human colon adenocarcinoma (Caco-2) cells were obtained from the
American Type Culture Collection (ATCC, Rockville, MD, USA). Stocks of Caco-2
cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM medium,
Gibco, Grand Island, NY) containing high glucose (4.5 g/l) plus 20% fetal bovine
serum (FBS, Gibco), 0.1 mM non-essential amino acids, 2 mM L-glutamine and
penicillin and streptomycin (Gibco). Cells used in this study were between passages
20 and 40. Caco-2 cells were cultured in 75 cm
2 T-flask (Corning, USA) at 37uC, 5%
CO2, with constant humidity controlled environment. The medium was replaced
twice a week. Cells were subcultured when they reached 80–90% confluence at a split
ratio of 1510 using 0.05% trypsin-0.02% EDTA (Gibco)
Caco-2 cell absorption assay. Flasks with Caco-2 cells which were 90–100%
confluent were harvested with trypsin/EDTA, neutralized with serum-containing
medium, and the cells were harvested by centrifugation. The cell pellet was
resuspended in a serum-free medium consisting of the Basal Seeding medium (BD
Biosciences)andMito
1SerumExtender(BDBiosciences)andseededonto6-wellsize
Cell Culture Inserts (Corning, NY) at a concentration of 6310
5cells/cm
2. Theinserts
contain a 0.4 mm polyester microporous membrane with collagen type I. The seeding
medium was replaced with Enterocytes Differentiation medium (BD Biosciences)
after 24 hours. The differentiation medium was replaced every 48 hours thereafter
and the cells were maintained at 37uC, 95% relative humidity, and 5% CO2. After
three days of incubation in the Enterocytes Differentiation medium, the Caco-2 cell
monolayers were used for the permeability studies. Physiologically and
morphologically well-developed Caco-2 cell monolayers with transepithelial
electrical resistance (TEER) values greater than 300 V cm
2 were used for the studies.
ThetransportmediumusedforthesestudieswasmodifiedHankbuffercontaining
10 mM HEPES at pH 7.5. Prior to all experiments,each monolayer was washed twice
with buffer and their TEER was measured to ensure the integrity of the monolayers.
Theapicaltobasolateral(AtoB)transportofverapamilwasmeasuredintheabsence
and presence of the test compound. The concentration of verapamil used was 100
mg/ml. The studies were initiated by adding an appropriate volume of buffer con-
tainingverapamil tothe apical(AtoBtransport)side ofthe monolayer. Thevolumes
of the apical and basolateral compartments were 1.6 and 2.8 ml, respectively, and 50
ml of ‘‘untreated’’ and ‘‘treated’’ RYR extract were added to the apical compartment
of the monolayer (final concentration at 0.5 mg/ml). The monolayers were then
Figure 4 | Effects of ‘‘untreated’’ and ‘‘treated’’ RYR extract on the
permeability coefficients (Peff (A–B)) of verapamil in the CaCO-2
absorptionstudy,finalconcentrationofsampleswas0.5 mg/ml. Dataare
expressed as mean 6 SD (n 5 4).
Figure 5 | Plasma concentrations of verapamil in the SD rats of ‘‘untreated’’ and ‘‘treated’’ RYR treated group and the control treated group (saline).
Data are expressed as mean 6 SD (n 5 4–6).
www.nature.com/scientificreports
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0 min, 10 min, 30 min, 60 min, 90 min, 120 min and 180 min; and from the apical
compartment at 0 min, during the incubation period and were analyzed for con-
centrations of verapamil by HPLC. The A to B permeability coefficient (Peff)o f
verapamil was calculated in the presence and absence of RYR water soluble extract.
Animal studies. Male Sprague-Dawley rats weighing 200–270 g were purchased
from the Animal Holding Unit of The National University of Singapore (NUS,
Singapore). All procedures were approved by the Institutional Animal Care and Use
committee, Nanyang Polytechnic (Singapore) and performed in accordance with
international standards. The animals were housed in conventional conditions under
controlled cycles of light/darkness (12 hr/12 hr) with a regulated temperature
(25uC). Twelve rats were allocated into two study groups with six animals in each
group.
The groups of animal that received ‘‘treated’’ and ‘‘untreated’’ RYR extract were
pre-treated with 1 ml of 100 mg/ml of ’’untreated’’ and ‘‘treated’’ RYR extract 30
minutespriortoverapamil(10 mg/kg)administration.Ratsinthecontrolgroupwere
pre-treated with 1 ml saline. The rats were then administrated with 10 mg/kg ver-
apamil. Blood samples were collected from the jugular vein at 0, 30, 60, 120, 240, 360
and 480 minutes after drug administration into a 1.5 ml eppendorf tube after they
were anesthetized with ketamine & xylazine (both at 100 mg/ml). The samples col-
lected were immediately centrifuged at 13,000 rpm for 2 minutes. The clear plasma
layerwastransferredtoacleantubeandthenequalvolumeofacentonitrilewasadded
to denature the proteins in the samples. After a 10 sec mixing via vortex, the samples
werecentrifugedat13,000 rpmfor2minutes.Thesupernatantsweretransferredinto
HPLC vials and then analyzed for levels of verapamil by HPLC. The peak area ratio
for an unknown sample was converted to concentration by reference to a calibration
curve of verapamil constructed with drug-free pooled rat plasma.
Calculation of absorption permeability coefficient (Peff). Absorption permeability
coefficient(Peff (A–B))inCaco-2cellmodelwasdeterminedbythefollowingequation:
Peff cm=s ðÞ ~dQ=dt=AC0
Where dQ/dt is the rate of appearance of the drug in receiver chamber (B), C0 is the
initial concentration of drug in the donor chamber (A), and A is the surface area
across which transport occurred.
Statistical analysis. All in vitro experiments were conducted in triplicate sets. All
results are expressed as mean 6 SD (standard deviation). Statistical differences were
evaluated usingStudent’sunpaired t-testand one-way ANOVAwhen appropriate. A
p,0.05 was considered to be significantly different for all tests.
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